FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology, and concerns treating the nervous system, particularly lateral amyotrophic sclerosis. That is ensured by introducing recombinant glutamate oxaloacetate transaminase with oxaloacetate introduction background. Recombinant glutamate oxaloacetate transaminase is administered on the first day in dose of 4.38 units/kg, in the following days - in dose of 1.14 units/kg. Oxaloacetate is orally administered in dose of 100 mg a day. Drugs administration is performed till therapeutic effect is achieved.
EFFECT: such treatment regimen, including administration of glutamate oxaloacetate transaminase in low maintenance doses, provides effective treatment of amyotrophic lateral sclerosis with reduced side effects.
5 cl, 1 dwg, 3 ex, 3 tbl
